{"name":"Seer","slug":"seer","ticker":"SEER","exchange":"NASDAQ","domain":"seer.bio","description":"Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which co","hq":"Redwood City, CA","founded":0,"employees":"124","ceo":"Omid Farokhzad","sector":"Proteomics / Life Sciences Tools","stockPrice":1.76,"stockChange":-0.01,"stockChangePercent":-0.56,"marketCap":"$97M","metrics":{"revenue":16578000,"revenueGrowth":5,"grossMargin":51.1,"rdSpend":43874000,"netIncome":-73600000,"cash":185896992,"dividendYield":0,"peRatio":-1.6,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Seer-001 patent cliff ($10.0M at risk)","drug":"Seer-001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Seer Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Seer reported fourth quarter and full year 2023 financial results, with revenue of $13.4 million and a net loss of $43.6 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Seer Announces Collaboration with Leading Pharmaceutical Company","summary":"Seer announced a collaboration with a leading pharmaceutical company to develop and commercialize its proteomics platform for the diagnosis and treatment of cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNRnBPSWt3SlFDYmVLNlc0SXpVWGlySHFoaXU3NUpfLTJ2aURtZmxYY2I4NzVJajhUdmZLa0F0d0h2QWczV0YyLUxDUDFtRzlpOGN1U1Q0VmJuSUF4b1llSVdBbF9wOE01dFJDWUMxUG9kbnNiWW5oak9xSnZUTzhsbzZ6NndzcTBNZ3VXcjFLbjJnZG1ob3JoSkkwbGV5THdiOExUdFdwRHhXcGdhTWYtaFRZaWhROFR5RnN2Um9DMzN5dw?oc=5","date":"2026-04-03","type":"regulatory","source":"Supply & Demand Chain Executive","summary":"SEER Robotics Debuts “All Robots, One Platform” Vision - Supply & Demand Chain Executive","headline":"SEER Robotics Debuts “All Robots, One Platform” Vision - Supply & Demand Chain Executive","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5QRl9iYVJlOW84Vm56ajBxNWJvbzVMdU9QNWFVcFZUMFZ4d1lUYTg0YXk3UGprbGltOFktYlQ5RVFrc3pzeUQtRmFFaXJxYWpQZXFIZjY5ZkExVVJrcHM0R3hUT3M5RWR2?oc=5","date":"2026-01-08","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Cybin D/B/A Helus Pharma (HELP) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada","headline":"Cybin D/B/A Helus Pharma (HELP) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQWHlZeHhsV3dJRTRqZU5JVWFIbnYtNUl5dVFhVktrdmozRXJqYldkVFRqakxIX2t1TjNaZ0hMX3BWaGtPV0xvYzJnNVpXQTR5M2xuQWkzVElyUFhqbjBCR2E1dlozTFNBZi0yb3paMlQ1X3hiQW9fSTQ5cVZvcndsbFBSRnE1VXFhRGNJZzhiR3pPbUdKZkFjazNabVNZVjNLZC1zWXhQRmlzUVVaSFRBaXpVYkxNRXVaYXJv?oc=5","date":"2026-01-07","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About Seer Inc: Is This ‘Future of Biotech’ Stock Secretly on Clearance? - AD HOC NEWS","headline":"The Truth About Seer Inc: Is This ‘Future of Biotech’ Stock Secretly on Clearance?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE15XzY3Qml0SDBidnRBclZRdlp1RVdEX1Vmd1JmZF9HV21oS3NCbjZ6LTZ2N3hReUxrdVNUM19EWHRBcTNRakNVR2NOWGRxM2dad1hLT2hnRGRXc1M2NjBONHcwVTdNQQ?oc=5","date":"2026-01-05","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Cybin D/B/A Helus Pharma (HELP) Valuation Measures & Financial Statistics - Yahoo! Finance Canada","headline":"Cybin D/B/A Helus Pharma (HELP) Valuation Measures & Financial Statistics - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPNGNUa3AzMU5BcXVNamVTX2JBbkNzalV1eXJHSGZKRHczb0lsWEFUTE5MOVJhVkRNcFhuLU9aQXdCbVpPcFlaSlpwYnJzWFc1bnhPOVlzRjZwbm82aVVwelFfeUFyUmYtREZjRmhSbDhXNW80d1BvdGlTd1pvR1hOb1hpZUpOQTVmSFc4dTZ3?oc=5","date":"2025-12-29","type":"pipeline","source":"조선일보","summary":"K-Bio Stocks Surge 80%, Expert Predicts Continued Growth Next Year - 조선일보","headline":"K-Bio Stocks Surge 80%, Expert Predicts Continued Growth Next Year - 조선일보","sentiment":"neutral"},{"date":"2025-12-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE95WTdwNnBxYkc1bjRMeFJHVE5RLUQ1N2xCMkxNX1hZVThWcWxoMlk0eGZaS3Zabi1KN2N6LWkzVGpGM0RKQVRpWVh4bE5PbVFDMGNMRWUxVjVVTHJCX3VOcC1QQjItYUx6Zl9VVXV30gFyQVVfeXFMUEJqYk9idG1vbGI5UnNxWW9CamR1Yk9reG9iWl9WU1Y3LUJXVlhVWE5SUVl0aXJ0MlZqWk9DMWNzMzNmYXBELVdLNXhpMFNCalFIbWREVThuWHFaN0VzelljOEZtbC15VlpnZVFCeGlVT1Zn?oc=5","date":"2025-07-17","type":"pipeline","source":"koreabiomed.com","summary":"Daewoong unveils reusable system for wearable ECG device - koreabiomed.com","headline":"Daewoong unveils reusable system for wearable ECG device","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-16","type":"pipeline","source":"simplywall.st","summary":"US$3.00: That's What Analysts Think Seer, Inc. (NASDAQ:SEER) Is Worth After Its Latest Results - simplywall.st","headline":"US$3.00: That's What Analysts Think Seer, Inc. (NASDAQ:SEER) Is Worth After Its Latest Results","sentiment":"neutral"}],"patents":[{"drugName":"Seer-001","drugSlug":"seer-001","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":10000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":6,"keyCompetitors":["Biogen","Roche","Illumina"],"therapeuticFocus":["Oncology","Rare Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":16578000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":16578000,"period":"2025-12-31"},{"value":14170000,"period":"2024-12-31"},{"value":14170000,"period":"2024-12-31"},{"value":16661000,"period":"2023-12-31"},{"value":16661000,"period":"2023-12-31"}],"grossProfit":8006000,"grossProfitHistory":[{"period":"2025-12-31","value":8006000},{"period":"2024-12-31","value":6832000},{"period":"2023-12-31","value":7027000},{"period":"2022-12-31","value":6285000}],"rdSpend":43874000,"rdSpendHistory":[{"period":"2025-12-31","value":43874000},{"period":"2024-12-31","value":50585000},{"period":"2023-12-31","value":53019000},{"period":"2022-12-31","value":45797000}],"sgaSpend":42583000,"operatingIncome":-77992000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-77992000},{"period":"2024-12-31","value":-100101000},{"period":"2023-12-31","value":-103463000},{"period":"2022-12-31","value":-97235000}],"netIncome":-73600000,"netIncomeHistory":[{"period":"2025-12-31","value":-73600000},{"period":"2024-12-31","value":-86599000},{"period":"2023-12-31","value":-86277000},{"period":"2022-12-31","value":-92966000}],"eps":-1.28,"epsHistory":[{"period":"2025-12-31","value":-1.28},{"period":"2024-12-31","value":-1.39},{"period":"2023-12-31","value":-1.35},{"period":"2022-12-31","value":-1.49}],"cash":47285000,"cashHistory":[{"period":"2025-12-31","value":47285000},{"period":"2024-12-31","value":40753000},{"period":"2023-12-31","value":32499000},{"period":"2022-12-31","value":53208000}],"totalAssets":296083000,"totalLiabilities":36776000,"totalDebt":23652000,"equity":259307000,"operatingCashflow":-44448000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-44448000},{"period":"2024-12-31","value":-46109000},{"period":"2023-12-31","value":-59065000},{"period":"2022-12-31","value":-60780000}],"capex":-1797000,"capexHistory":[{"period":"2025-12-31","value":-1797000},{"period":"2024-12-31","value":-3584000},{"period":"2023-12-31","value":-7309000},{"period":"2022-12-31","value":-10265000}],"freeCashflow":-46245000,"dividendsPaid":null,"buybacks":-10199000,"employees":124,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":9826000,"ebit":-17385000,"ebitda":-15878000,"period":"2025-12-31","revenue":4073000,"epsBasic":-0.29,"netIncome":-15994000,"rdExpense":9742000,"epsDiluted":-0.29,"grossProfit":2055000,"operatingIncome":-17385000},{"sga":10659000,"ebit":-19346000,"ebitda":-17891000,"period":"2025-09-30","revenue":3969000,"epsBasic":-0.32,"netIncome":-18234000,"rdExpense":10797000,"epsDiluted":-0.32,"grossProfit":1958000,"operatingIncome":-19346000},{"sga":10656000,"ebit":-20530000,"ebitda":-18986000,"period":"2025-06-30","revenue":3932000,"epsBasic":-0.33,"netIncome":-19424000,"rdExpense":11985000,"epsDiluted":-0.33,"grossProfit":1992000,"operatingIncome":-20530000},{"sga":11442000,"ebit":-20731000,"ebitda":-19133000,"period":"2025-03-31","revenue":4145000,"epsBasic":-0.34,"netIncome":-19948000,"rdExpense":11350000,"epsDiluted":-0.34,"grossProfit":2001000,"operatingIncome":-20731000},{"sga":12894000,"ebit":-23488000,"ebitda":-21880000,"period":"2024-12-31","revenue":3949000,"epsBasic":-0.37,"netIncome":-21742000,"rdExpense":12619000,"epsDiluted":-0.37,"grossProfit":1974000,"operatingIncome":-23488000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.76,"previousClose":1.77,"fiftyTwoWeekHigh":2.41,"fiftyTwoWeekLow":1.65,"fiftyTwoWeekRange":"1.65 - 2.41","fiftyDayAverage":1.82,"twoHundredDayAverage":1.97,"beta":1.64,"enterpriseValue":-62380232,"forwardPE":-1.6,"priceToBook":0.38,"priceToSales":5.85,"enterpriseToRevenue":-3.76,"enterpriseToEbitda":0.87,"pegRatio":0,"ebitda":-71888000,"ebitdaMargin":0,"freeCashflow":-27648000,"operatingCashflow":-44448000,"totalDebt":23652000,"debtToEquity":9.1,"currentRatio":12.84,"returnOnAssets":-14.7,"returnOnEquity":-25.1,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":1,"targetMeanPrice":4,"targetHighPrice":4,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":9.8,"institutionHeldPercent":52.4,"sharesOutstanding":55065984,"floatShares":41542614,"sharesShort":427617,"shortRatio":0.95,"shortPercentOfFloat":0.8,"epsTrailing":-1.28,"epsForward":-1.08,"revenuePerShare":0.29,"bookValue":4.61,"officers":[{"age":56,"name":"Dr. Omid C. Farokhzad M.D., Ph.D.","title":"Founder, CEO, & Chair of the Board of Directors"},{"age":57,"name":"Mr. David R. Horn","title":"President,Treasurer & CFO"},{"age":null,"name":"Kenny  Ross","title":"Chief Operations & Product Officer"},{"age":null,"name":"Ms. Marissa  Dixon","title":"Chief People Officer"},{"age":null,"name":"Dr. Serafim  Batzoglou Ph.D.","title":"Chief Data Officer"},{"age":null,"name":"Mr. Martin  Goldberg Ph.D.","title":"Senior Vice President of Product Development"},{"age":null,"name":"Dr. Asim  Siddiqui Ph.D.","title":"Senior Vice President of Research & Tech Development"},{"age":null,"name":"Mr. Anthony  Bazarko","title":"Chief Commercial Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://seer.bio","phone":"650 453 0000"}}